Current heart valve repair (annuloplasty) rings and bands are designed for symmetric dilatation. The IMR ETlogix annuloplasty ring is the first asymmetric ring designed to treat asymmetric dilatation.

• Corrects for the valvular insufficiency associated with Type IIIb mitral regurgitation.
• Decreased anteroposterior (AP) distance increases leaflet coaptation.
• Asymmetric 3-D reduced P2-P3 curvature design compensates for tethered P3 segment.
• Increased sewing margin in the P2-P3 region, marked with suture, designed to accommodate a double-suture row.

Edwards' IMR ETlogix Ring was created through collaboration with several key innovators in the field of heart valve repair, including Professor Alain Carpentier, chairman of the Department of Cardiovascular Surgery at the Hopital Europeen Georges Pompidou in Paris; Dr. Patrick McCarthy, director of cardiac transplantation at The Cleveland Clinic Foundation; and Dr. David Adams, professor and chairman of the Department of Cardiothoracic Surgery at Mount Sinai Medical Center, New York.

Dr. Adams is a consultant to Edwards Lifesciences and receives compensation from the company for these services. As the co-inventor of the Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring, both Dr. Adams and Mount Sinai School of Medicine receive royalties from Edwards Lifesciences in connection with the sale of this product, but do not receive any royalties when he implants the device in his patients at Mount Sinai.